Literature DB >> 14965445

A unique model system for tumor progression in GBM comprising two developed human neuro-epithelial cell lines with differential transforming potential and coexpressing neuronal and glial markers.

Anjali Shiras1, Arti Bhosale, Varsha Shepal, Ravi Shukla, V S Baburao, K Prabhakara, Padma Shastry.   

Abstract

The molecular mechanisms involved in tumor progression from a low-grade astrocytoma to the most malignant glioblastoma multiforme (GBM) have been hampered due to lack of suitable experimental models. We have established a model of tumor progression comprising of two cell lines derived from the same astrocytoma tumor with a set of features corresponding to low-grade glioma (as in HNGC-1) and high-grade GBM (as in HNGC-2). The HNGC-1 cell line is slow-growing, contact-inhibited, nontumorigenic, and noninvasive, whereas HNGC-2 is a rapidly proliferating, anchorage-independent, highly tumorigenic, and invasive cell line. The proliferation of cell lines is independent of the addition of exogenous growth factors. Interestingly, the HNGC-2 cell line displays a near-haploid karyotype except for a disomy of chromosome 2. The two cell lines express the neuronal precursor and progenitor markers vimentin, nestin, MAP-2, and NFP160, as well as glial differentiation protein S100beta. The HNGC-1 cell line also expresses markers of mature neurons like Tuj1 and GFAP, an astrocytic differentiation marker, hence contributing toward a more morphologically differentiated phenotype with a propensity for neural differentiation in vitro. Additionally, overexpression of epidermal growth factor receptor and c-erbB2, and loss of fibronectin were observed only in the HNGC-2 cell line, implicating the significance of these pathways in tumor progression. This in vitro model system assumes importance in unraveling the cellular and molecular mechanisms in differentiation, transformation, and gliomagenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14965445      PMCID: PMC1502577          DOI: 10.1016/s1476-5586(03)80036-2

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  41 in total

1.  Neuronal and glial properties coexist in a novel mouse CNS immortalized cell line.

Authors:  G L Colucci-D'Amato; A Tino; R Pernas-Alonso; J M ffrench-Mullen; U di Porzio
Journal:  Exp Cell Res       Date:  1999-11-01       Impact factor: 3.905

2.  Coexpression of nestin in neural and glial cells in the developing human CNS defined by a human-specific anti-nestin antibody.

Authors:  C A Messam; J Hou; E O Major
Journal:  Exp Neurol       Date:  2000-02       Impact factor: 5.330

3.  Aberrant localization of the neuronal class III beta-tubulin in astrocytomas.

Authors:  C D Katsetos; L Del Valle; J F Geddes; M Assimakopoulou; A Legido; J C Boyd; B Balin; N A Parikh; T Maraziotis; J P de Chadarevian; J N Varakis; R Matsas; A Spano; A Frankfurter; M M Herman; K Khalili
Journal:  Arch Pathol Lab Med       Date:  2001-05       Impact factor: 5.534

4.  Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma.

Authors:  Y Sonoda; T Ozawa; K D Aldape; D F Deen; M S Berger; R O Pieper
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

5.  Microtubule-associated protein 2 (MAP-2) is expressed in low and high grade diffuse astrocytomas.

Authors:  S B Wharton; K K Chan; I R Whittle
Journal:  J Clin Neurosci       Date:  2002-03       Impact factor: 1.961

Review 6.  Gli and hedgehog in cancer: tumours, embryos and stem cells.

Authors:  Ariel Ruiz i Altaba; Pilar Sánchez; Nadia Dahmane
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

7.  Nestin as a marker for proliferative endothelium in gliomas.

Authors:  Ken-ichi Sugawara; Hideyuki Kurihara; Mitsuko Negishi; Nobuhito Saito; Yoichi Nakazato; Tomio Sasaki; Toshiyuki Takeuchi
Journal:  Lab Invest       Date:  2002-03       Impact factor: 5.662

8.  Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells.

Authors:  Christopher Y Thomas; Michael Chouinard; Michael Cox; Sarah Parsons; Melody Stallings-Mann; Roy Garcia; Richard Jove; Robert Wharen
Journal:  Int J Cancer       Date:  2003-03-10       Impact factor: 7.396

9.  Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro.

Authors:  Tatyana N Ignatova; Valery G Kukekov; Eric D Laywell; Oleg N Suslov; Frank D Vrionis; Dennis A Steindler
Journal:  Glia       Date:  2002-09       Impact factor: 7.452

10.  Malignant transformation in human chondrosarcoma cells supported by telomerase activation and tumor suppressor inactivation.

Authors:  James A Martin; Erin Forest; Joel A Block; Aloysius J Klingelhutz; Brent Whited; Steven Gitelis; Andrew Wilkey; Joseph A Buckwalter
Journal:  Cell Growth Differ       Date:  2002-09
View more
  12 in total

Review 1.  A review of the past, present, and future directions of neoplasia.

Authors:  Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

2.  Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas.

Authors:  Ganeshkumar Rajendran; Karthik Shanmuganandam; Ameya Bendre; Dattatraya Muzumdar; Dattatreya Mujumdar; Abhay Goel; Anjali Shiras
Journal:  J Neurooncol       Date:  2011-01-13       Impact factor: 4.130

3.  MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells.

Authors:  Sandhya B Rani; Sachin Shivaji Rathod; Shanmuganandam Karthik; Navjot Kaur; Dattatraya Muzumdar; Anjali S Shiras
Journal:  Neuro Oncol       Date:  2013-06-28       Impact factor: 12.300

4.  Sumoylation of vimentin354 is associated with PIAS3 inhibition of glioma cell migration.

Authors:  Liming Wang; Jian Zhang; Sipra Banerjee; Laura Barnes; Laura Barnes; Venkateswara Sajja; Yiding Liu; Baochuan Guo; Yuping Du; Mukesh K Agarwal; David N Wald; Qin Wang; Jinbo Yang
Journal:  Oncotarget       Date:  2010-11

5.  Nestin expression in the cell lines derived from glioblastoma multiforme.

Authors:  Renata Veselska; Petr Kuglik; Pavel Cejpek; Hana Svachova; Jakub Neradil; Tomas Loja; Jirina Relichova
Journal:  BMC Cancer       Date:  2006-02-02       Impact factor: 4.430

6.  Differential expression of p42.3 in low- and high-grade gliomas.

Authors:  Weiqing Wan; Xiaoqing Xu; Guijun Jia; Wenmei Li; Junmei Wang; Tong Ren; Zhen Wu; Junting Zhang; Liwei Zhang; Youyong Lu
Journal:  World J Surg Oncol       Date:  2014-06-14       Impact factor: 2.754

7.  Attenuation of Tumor Suppressive Function of FBXO16 Ubiquitin Ligase Activates Wnt Signaling In Glioblastoma.

Authors:  Mohsina Khan; Dattatraya Muzumdar; Anjali Shiras
Journal:  Neoplasia       Date:  2018-12-05       Impact factor: 5.715

8.  Stimulation of glioma cell motility by expression, proteolysis, and release of the L1 neural cell recognition molecule.

Authors:  Muhua Yang; Shalini Adla; Murali K Temburni; Vivek P Patel; Errin L Lagow; Owen A Brady; Jing Tian; Magdy I Boulos; Deni S Galileo
Journal:  Cancer Cell Int       Date:  2009-10-29       Impact factor: 5.722

9.  Expression and regulation of prostate apoptosis response-4 (Par-4) in human glioma stem cells in drug-induced apoptosis.

Authors:  Jayashree C Jagtap; Parveen Dawood; Reecha D Shah; Goparaju Chandrika; Kumar Natesh; Anjali Shiras; Amba S Hegde; Deepak Ranade; Padma Shastry
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

10.  Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways.

Authors:  Sachin S Rathod; Sandhya B Rani; Mohsina Khan; Dattatraya Muzumdar; Anjali Shiras
Journal:  FEBS Open Bio       Date:  2014-05-22       Impact factor: 2.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.